Xuanzhu Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Xuanzhu Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug safety check: how does anaprazole affect liver, kidney, and elderly patients? Results expected Oct 2026 (estimated)
- New acid reducer shows promise in fighting stomach bug Results expected Feb 2027 (estimated)
-
New acid reducer shows promise in fighting stomach bug
Disease control Not yet recruitingThis Phase 3 trial tests whether a new acid-reducing drug, anaprazole, works better than the standard drug esomeprazole when used with bismuth and two antibiotics to treat H. pylori infection. About 556 adults in China will take either anaprazole or esomeprazole pills twice daily…
Phase 3 • Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug safety check: how does anaprazole affect liver, kidney, and elderly patients?
Knowledge-focused Not yet recruitingThis study looks at how the drug anaprazole sodium is processed by the body and whether it is safe for people with liver or kidney issues, as well as for older adults. About 60 participants will be enrolled to measure drug levels and track any side effects. The goal is to underst…
Phase 4 • Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Healthy volunteers needed to test drug interaction
Knowledge-focused Not yet recruitingThis study looks at how the antibiotic rifampin changes the way the body processes anaprazole, a stomach acid reducer. It involves 24 healthy adults aged 18-45. The goal is to measure drug levels and check for side effects when both drugs are taken together.
Phase 4 • Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC